Bayer Pharma Aktiengesellschaft

Boehringer Ingelheim Kg

Bayer Intellectual Property Gmbh

Bayer Schering Pharma Ag

Boehringer Ingelheim Pharma Kg

Schering Aktiengesellschaft

Boehringer Ingelheim Pharma Gmbh & Co Kg

Bayer Aktiengesellschaft

Deutsches Krebsforschungszentrum Heidelberg

Hans Briem

Gerhard Siemeister

Georg Speck

Philip Lienau

Birgit Jung

Horst Dollinger

Gerd Schnorrenberg

Antje Margret Wengner

Knut Eis

Benjamin Bader

Anne Mengel

Volker Schulze

Franz Esser

Marcus Koppitz

Ulf Bömer

Lars Bärfacker

Karl-Heinz Thierauch

Dirk Kosemund

Ulrich Lücking

Ulrich Klar

Christoph Hoenke

Ralf Anderskewitz

Hans Schick

Mark Jean Gnoth

Hartmut Rehwinkel

William Johnston Scott

Wolfgang Schwede

Joachim Kuhnke

Roland Neuhaus

Klaus Fuchs

Frank Himmelsbach

Gary Bruce Phillips

Matthias Grauert

Pierre Wasnaire

Alexandros Vakalopoulos

Matthias Hoffmann

Thomas Ernst Müller

Hans-Georg Lerchen

Brad Owen Buckman

Katja Zimmermann

Bernd Buchmann

Martina Schäfer

Duy Nguyen

Niels Lindner

Norbert Schmees

Simon Holton

Wilhelm Bone

Marion Hitchcock

Georg Kettschau

Amaury Ernesto Fernandez-Montalvan

Stefan Prechtl

Jens Schröder

Stuart Ince

Lars Wortmann

Julien Lefranc

Hartmut Schirok

Keith Graham

Bernd Disse

Antonius Ter Laak

Damian O Arnaiz

Christoph-Stephan Hilger

Ursula Mönning

Ingo Hartung

Hans Michael Jennewein

Joanna Grudzinska-Goebel

Dieter Moosmayer

Andrea Hägebarth

Olaf Prien

Detlef Stöckigt

Oliver Politz

Arwed Cleve

Shendong Yuan

Joerg Keldenich

Monica J Kochanny

Cornelia Dorner-Ciossek

Ulrich Bothe

Helmut Sonnenschein

Klaus Klinder

Joachim Telser

Thomas Weiser

Mario Lobell

Wolf-Dietrich Bechtel

Clara Christ

Nicole Teusch

Franz Von Nussbaum

Richard L Feldman

Jürgen Klar

Martin Krueger

Peter Esperling

Martin Michels

Christian Stegmann

Heinz Graubaum

Adrian Carter

Judi Bryant

Kersten Matthias Gericke

Georges Von Degenfeld

Hermann Kuenzer

Christoph Huwe

Tobias Heinrich

Dirk Brohm

The present invention relates to substituted 2-(morpholin-4-yl)-1,7-naphthyridine compounds of general formula (I) or (Ib), to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyperproliferative disease as a sole agent or in combination with other active ingredients.

2-(morpholin-4-yl)-1,7-naphthyridines

The present invention covers heteroarylbenzimidazole compounds of general formula (I) in which R, R, R, Rand Rare as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of hyperproliferative and/or inflammatory disorders, as a sole agent or in combination with other active ingredients. 

Heteroarylbenzimidazole compounds

Compounds of formula (I) which are inhibitors of Bub 1 kinase, processes for their production and their use as pharmaceuticals.

Substituted benzylindazoles for use as BUB1 kinase inhibitors in the treatment of hyperproliferative diseases

Compounds of formula (I) which are inhibitors of Bub1 kinase, processes for their production and their use as pharmaceuticals. 

3-amino-1,5,6,7-tetrahydro-4H-indol-4-ones

Compound of formula (I), processes for their production and their use as pharmaceuticals. 

4H-pyrrolo[3,2-C]pyridin-4-one derivatives

Compounds of formula (I) as defined herein and their use as pharmaceuticals. 

Benzyl substituted indazoles as BUB1 inhibitors

Compounds of formula (I) as described herein, processes for their production and their use as pharmaceuticals. 

1H-pyrrol-3-amines

Substituted benzylindazoles for use as Bub1 kinase inhibitors in the treatment of hyperproliferative diseases

Compounds of formula (I) as described herein processes for their production and their use as anti-cancer agents. 

The present application relates to novel (3-hydroxyphenyl)amino-substituted pyrido[2,3-b][1,5]benzodiazepin-5-one derivatives, to processes for preparation thereof, to the use thereof alone or in combination for treatment and/or prevention of diseases and to the use thereof for production of medicaments for treatment and/or prevention of diseases, especially of angiogenic disorders and hyperproliferative disorders in which neovascularization plays a role, for example ophthalmological disorders and cancers and tumours. Such treatments can be effected as monotherapy or else in combination with other medicaments or further therapeutic measures.

Substituted pyridobenzodiazepinone-derivatives and use thereof

The present invention relates to substituted 2-(morpholin-4-yl)-1,7-naphthyridine compounds of general formula (I) or (1b), to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyperproliferative disease as a sole agent or in combination with other active ingredients. 

Compounds of formula (I), and their use as pharmaceuticals. 

Substituted benzylpyrazoles

Compounds of formula (I), which are inhibitors of Bub1 kinase, processes for their production and their use as pharmaceuticals. 

Heteroaryl substituted pyrazoles

Compounds of formula (I), processes for their preparation and their use as pharmaceuticals. 

Growing community of inventors

Berlin, Germany

Hans Briem